Strategies to Isolate and Expand Myeloma Specific T-cells Using Autologous B Cells as Antigen Presenting Cell B-APC
- To evaluate the feasibility of expanding myeloma-specific T cells using autologous ex
vivo expanded B cells loaded with myeloma antigens as antigen-presenting cells (B-APCs)
in peripheral blood and bone marrow samples from patients with multiple myeloma.
- To examine the feasibility of selecting and expanding myeloma-specific T cells ex vivo
using interferon γ release and CD3/CD28 stimulation.
OUTLINE: Peripheral blood and bone marrow samples are collected periodically for laboratory
studies. Samples are analyzed to assess the feasibility of expanding autologous B cells ex
vivo using CD40L and IL-4; the antigen-presenting phenotype of autologous B-cell
antigen-presenting cells (B-APCs) using flow cytometry; and the antigen-presenting function
of B-APCs using ELISPOT and chromium-release assay. Myeloma-specific interferon γ secreting
T cells are isolated and selected using Miltenyi beads. The selected myeloma-specific T
cells are expanded ex vivo using anti CD3/CD28 beads.
Observational Model: Case-Only, Time Perspective: Prospective
Percentage of myeloma-specific T cells ex vivo expanded using flow cytometry
Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
Zaid Al-Kadhimi, MD
Barbara Ann Karmanos Cancer Institute
United States: Food and Drug Administration
|Barbara Ann Karmanos Cancer Institute||Detroit, Michigan 48201|